LENZ Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.7%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$4.25next fiscal year
Monitoring Framework
Key Performance Indicators
VIZZ Paid and Filled Prescriptions (Quarterly) Quarterly25K
VIZZ Cumulative Paid and Filled Prescriptions Since Launch Quarterly46K
Unique Prescribing Eye Care Professionals (ECPs) Quarterly10K
Quarterly Net Product Revenue (USD) Quarterly1.7M
Watch Items
- New patient adoption rate and DTC marketing campaign effectivenessTrigger: Adoption pace falling significantly below target trajectoryAction: Expand sales force, optimize direct-to-consumer (DTC) marketing spend, and increase ECP engagement initiatives.
- Patient refill rates and cohort maturityTrigger: Refill rates falling below expectations in the second half of 2026Action: Analyze patient cohort data, address barriers to adherence, and adjust patient sampling/education programs.
- Global regulatory approvals (EMA, MHRA, and Asian markets)Trigger: Delay or rejection of Marketing Authorization Applications (MAA)Action: Engage with regulatory bodies, address outstanding questions, and coordinate with regional partners (e.g., Everest Medicines, Lunatus).
Research as of 19 Jun 2026